Pulmicort Aerosol, Powder
NDC Package 61269-518-12
Package Information
Pulmicort (budesonide) aerosols is the use of PULMICORT FLEXHALER is contraindicated in the following conditions:•Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.•Severe hypersensitivity to milk proteins or any ingredients of PULMICORT FLEXHALER [see Warnings and Precautions (5.3), Description (11)]. This formulation utilizes a aerosol, powder delivery system. Marketed by H2-pharma Llc, this product is identified by NDC 61269-518 and is authorized under FDA application NDA021949.
Identification & Billing
- RxCUI: 966522 - budesonide 180 MCG/INHAL Dry Powder Inhaler, 120 ACTUAT
- RxCUI: 966522 - 120 ACTUAT budesonide 0.18 MG/ACTUAT Dry Powder Inhaler
- RxCUI: 966522 - budesonide 0.18 MG/ACTUAT (0.16 MG/ACTUAT from the mouthpiece) Dry Powder Inhaler, 120 ACTUAT
- RxCUI: 966522 - budesonide 180 MCG/ACTUAT Dry Powder Inhaler, 120 ACTUATS
- RxCUI: 966524 - Pulmicort Flexhaler 180 MCG/INHAL Dry Powder Inhaler, 120 ACTUAT
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 61269 - H2-pharma Llc
- 61269-518 - Pulmicort
- 61269-518-12 - 1 INHALER in 1 CARTON / 120 AEROSOL, POWDER in 1 INHALER
- 61269-518 - Pulmicort
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61269-518-12 identifies a specific commercial package of 1 inhaler in 1 carton / 120 aerosol, powder in 1 inhaler of Pulmicort Flexhaler, a human prescription drug labeled by H2-pharma Llc. This aerosol, powder is formulated for respiratory (inhalation) use and contains budesonide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by H2-pharma Llc on March 19, 2007. The current certification is valid through December 31, 2026.
How is this H2-pharma Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61269051812. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.